Iovance Biotherapeutics, Inc. (IOVA)

NASDAQHealth CareBiotechnologySnapshot 2026-11-04

$8.70-1.47%

Close 2026-11-04 · 1-day change

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge Iovance Biotherapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for IOVA yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve operating income and cash flow	The company is improving cost discipline, reducing operating losses from -$114M to -$81M.	Intact	Operating income worse than -$81M or cash flow worse than -$72M	Operating income: $-51.905M FY2026-Q2; GAAP. Published target: Operating income better than -$81M and cash flow better than -$72M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-51,905,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Meet 2Q26 revenue guidance of $86M-$88M	Quarterly revenue guidance for 2Q26 is $86M-$88M, showing steady progress.	Intact	2Q26 revenue falls below $86M	Revenue: $99.313M FY2026-Q2; GAAP. Published target: $86M-$88M revenue. The target does not explicitly identify fiscal versus calendar quarters. Aug 6, 202699,313,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain regulatory approvals and trial progress	Regulatory approvals boost confidence in its cancer immunotherapy products.	Intact	Loss of key regulatory approvals or trial setbacks	24.6% response rate in lung cancer trial Recent news confirms advancing clinical trials with positive response rates in lung cancer and melanoma, with no reported regulatory losses or setbacks. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve FY26 revenue of $350M-$370M	A primary condition in Iovance Biotherapeutics, Inc.'s published investment case. The stated target is $350M-$370M total revenue.	Intact	Total revenue falls below $350M in FY26	Revenue: $99.313M FY2026-Q2; GAAP. Published target: $350M-$370M total revenue. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202699,313,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.17

$-0.31 → $-0.17 · observed estimates

FY2027 revenue$0.60B

$0.50B → $0.60B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.31	$496,226,881	6 / 6
2026-07-25	$-0.31	$496,226,881	6 / 6
2026-07-26	$-0.32	$496,276,260	7 / 8
2026-07-27	$-0.32	$496,276,260	7 / 8
2026-07-28	$-0.31	$496,226,881	6 / 6
2026-07-29	$-0.32	$496,276,260	7 / 8
2026-07-30	$-0.32	$496,276,260	7 / 8
2026-07-31	$-0.32	$496,536,360	7 / 8
2026-08-01	$-0.31	$496,486,985	6 / 6
2026-08-02	$-0.32	$496,536,360	7 / 8
2026-08-03	$-0.32	$496,536,360	7 / 8
2026-08-04	$-0.31	$496,486,985	6 / 6
2026-08-05	$-0.32	$496,536,360	7 / 8
2026-08-06	$-0.32	$496,536,360	7 / 8
2026-08-07	$-0.31	$496,486,985	6 / 6
2026-08-08	$-0.31	$496,486,985	6 / 6
2026-08-09	$-0.28	$536,111,610	7 / 8
2026-08-10	$-0.31	$496,486,985	6 / 6
2026-08-12	$-0.31	$496,486,985	6 / 6
2026-08-13	$-0.31	$496,486,985	6 / 6
2026-08-14	$-0.31	$496,486,985	6 / 6
2026-08-15	$-0.31	$496,486,985	6 / 6
2026-08-16	$-0.31	$496,486,985	6 / 6
2026-08-17	$-0.31	$496,486,985	6 / 6
2026-08-18	$-0.31	$496,486,985	6 / 6
2026-08-19	$-0.31	$496,486,985	6 / 6
2026-08-20	$-0.26	$555,100,610	6 / 6
2026-08-21	$-0.23	$569,314,292	6 / 6
2026-08-22	$-0.23	$569,314,292	6 / 6
2026-08-23	$-0.23	$569,314,292	6 / 6
2026-08-24	$-0.23	$569,314,292	6 / 6
2026-08-25	$-0.23	$569,314,292	6 / 6
2026-08-26	$-0.25	$557,439,292	5 / 6
2026-08-27	$-0.25	$557,439,292	5 / 6
2026-08-28	$-0.25	$557,439,292	6 / 6
2026-08-29	$-0.25	$557,439,292	6 / 6
2026-08-30	$-0.25	$557,439,292	6 / 6
2026-08-31	$-0.25	$557,439,292	6 / 6
2026-09-01	$-0.25	$557,439,292	6 / 6
2026-09-02	$-0.25	$557,439,292	6 / 6
2026-09-03	$-0.25	$557,439,292	6 / 6
2026-09-04	$-0.25	$557,439,292	6 / 6
2026-09-05	$-0.25	$557,439,292	6 / 6
2026-09-06	$-0.25	$557,439,292	6 / 6
2026-09-07	$-0.25	$557,439,292	6 / 6
2026-09-08	$-0.25	$557,439,292	6 / 6
2026-09-09	$-0.25	$557,439,292	6 / 6
2026-09-10	$-0.25	$557,439,292	6 / 6
2026-09-11	$-0.25	$557,439,292	6 / 6
2026-09-12	$-0.25	$557,439,292	6 / 6
2026-09-13	$-0.25	$557,439,292	6 / 6
2026-09-14	$-0.25	$557,439,292	6 / 6
2026-09-15	$-0.25	$557,439,292	6 / 6
2026-09-16	$-0.25	$557,439,292	6 / 6
2026-09-17	$-0.25	$557,439,292	6 / 6
2026-09-18	$-0.23	$557,439,292	6 / 6
2026-09-19	$-0.23	$557,439,292	6 / 6
2026-09-20	$-0.23	$557,439,292	6 / 6
2026-09-21	$-0.23	$557,439,292	6 / 6
2026-09-22	$-0.23	$557,439,292	6 / 6
2026-09-23	$-0.23	$557,439,292	6 / 6
2026-09-24	$-0.23	$557,439,292	6 / 6
2026-09-25	$-0.23	$557,439,292	6 / 6
2026-09-26	$-0.23	$561,034,482	6 / 7
2026-09-27	$-0.23	$561,034,482	6 / 7
2026-09-28	$-0.23	$561,034,482	6 / 7
2026-09-29	$-0.23	$561,034,482	6 / 7
2026-09-30	$-0.21	$572,634,482	6 / 7
2026-10-01	$-0.21	$575,242,837	6 / 7
2026-10-02	$-0.21	$575,244,259	6 / 7
2026-10-03	$-0.21	$575,244,259	6 / 7
2026-10-04	$-0.21	$575,244,259	6 / 7
2026-10-05	$-0.21	$575,244,259	6 / 7
2026-10-06	$-0.21	$575,244,259	6 / 7
2026-10-07	$-0.21	$575,244,259	6 / 7
2026-10-08	$-0.21	$575,244,259	6 / 7
2026-10-09	$-0.19	$587,786,704	6 / 7
2026-10-10	$-0.19	$587,786,704	6 / 7
2026-10-11	$-0.19	$587,786,704	6 / 7
2026-10-12	$-0.19	$587,786,704	6 / 7
2026-10-13	$-0.19	$587,786,704	6 / 7
2026-10-14	$-0.17	$593,631,148	6 / 7
2026-10-15	$-0.17	$593,631,148	6 / 7
2026-10-16	$-0.17	$593,631,148	6 / 7
2026-10-17	$-0.17	$593,631,148	6 / 7
2026-10-18	$-0.17	$593,629,722	6 / 7
2026-10-19	$-0.17	$593,629,722	6 / 7
2026-10-20	$-0.17	$593,629,722	6 / 7
2026-10-21	$-0.17	$593,629,722	6 / 7
2026-10-22	$-0.17	$593,629,722	6 / 7
2026-10-23	$-0.17	$593,629,722	6 / 7
2026-10-24	$-0.17	$593,629,722	6 / 7
2026-10-25	$-0.17	$593,629,722	6 / 7
2026-10-26	$-0.17	$593,629,722	6 / 7
2026-10-27	$-0.17	$593,629,722	6 / 7
2026-10-28	$-0.17	$593,629,722	6 / 7
2026-10-29	$-0.17	$593,629,722	6 / 7
2026-10-30	$-0.17	$593,629,722	6 / 7
2026-10-31	$-0.17	$593,631,148	6 / 7
2026-11-01	$-0.17	$593,631,148	6 / 7
2026-11-02	$-0.17	$593,631,148	6 / 7
2026-11-03	$-0.17	$593,631,148	6 / 7
2026-11-04	$-0.17	$595,540,330	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-06-01	8	2
2026-07-01	8	2
2026-08-01	7	2
2026-09-01	8	2
2026-10-01	8	2
2026-11-01	7	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Oct 6–Nov 4 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSNov 3 · prior Aug 20

$7.00 → $8.00+14.3%

BarclaysOct 13 · prior Sep 17

$15.00 → $18.00+20.0%

Robert W. BairdOct 8 · prior Aug 7

$6.00 → $11.00+83.3%

$0$9.90$19.80

3 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve operating income and cash flowOperating income: $-51.905M
Meet 2Q26 revenue guidance of $86M-$88MRevenue: $99.313M
Achieve FY26 revenue of $350M-$370MRevenue: $99.313M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.1%Typical daily move · historical

Downside history

-46.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Iovance Biotherapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is a high-risk commercial-growth and clinical-development story, not an established profitable compounder. The long-term thesis is intact, with Amtagvi adoption showing progress, while pipeline advancement and a path to profitability remain less proven.

What's priced into Iovance Biotherapeutics, Inc.

The valuation evidence points to IOVA as cheap versus peers, with no measured premium and an expectations gap below the model’s baseline. Confidence in that comparison is low, so it does not establish that the shares are mispriced; the evidence says expectations appear justified and no fragility signals were triggered.

What the fundamentals likely do

Near term, revenue rose from the first to the second quarter of 2026, and management raised full-year guidance to $410 million to $420 million. Operating losses narrowed but remained substantial, and recent results included both a reported earnings beat and a prior miss. A guidance cut or continued weakness in employment could raise risks, while the available evidence does not confirm full-year delivery.

What Iovance Biotherapeutics, Inc. hinges on

Over the next few quarters, the key test is whether Amtagvi adoption supports the raised guidance and whether manufacturing changes continue to narrow operating losses. Over the multi-year view, progress in lifileucel programs beyond the current use matters, but the supplied evidence does not show substantive clinical delivery. Broader healthcare-sector strength is a possible tailwind, while weaker employment and sector results are risks.

Bottom line

For the next 1 to 3 years, IOVA’s thesis rests on continued commercial growth and better operating efficiency, with profitability and broader pipeline progress still unproven. The current evidence supports an intact but elevated-risk long-term thesis. Not investment advice.

Development preview · refreshed Nov 5, 2026Open Living FV detail

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.17

$-0.31 → $-0.17 · observed estimates

FY2027 revenue$0.60B

$0.50B → $0.60B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.31	$496,226,881	6 / 6
2026-07-25	$-0.31	$496,226,881	6 / 6
2026-07-26	$-0.32	$496,276,260	7 / 8
2026-07-27	$-0.32	$496,276,260	7 / 8
2026-07-28	$-0.31	$496,226,881	6 / 6
2026-07-29	$-0.32	$496,276,260	7 / 8
2026-07-30	$-0.32	$496,276,260	7 / 8
2026-07-31	$-0.32	$496,536,360	7 / 8
2026-08-01	$-0.31	$496,486,985	6 / 6
2026-08-02	$-0.32	$496,536,360	7 / 8
2026-08-03	$-0.32	$496,536,360	7 / 8
2026-08-04	$-0.31	$496,486,985	6 / 6
2026-08-05	$-0.32	$496,536,360	7 / 8
2026-08-06	$-0.32	$496,536,360	7 / 8
2026-08-07	$-0.31	$496,486,985	6 / 6
2026-08-08	$-0.31	$496,486,985	6 / 6
2026-08-09	$-0.28	$536,111,610	7 / 8
2026-08-10	$-0.31	$496,486,985	6 / 6
2026-08-12	$-0.31	$496,486,985	6 / 6
2026-08-13	$-0.31	$496,486,985	6 / 6
2026-08-14	$-0.31	$496,486,985	6 / 6
2026-08-15	$-0.31	$496,486,985	6 / 6
2026-08-16	$-0.31	$496,486,985	6 / 6
2026-08-17	$-0.31	$496,486,985	6 / 6
2026-08-18	$-0.31	$496,486,985	6 / 6
2026-08-19	$-0.31	$496,486,985	6 / 6
2026-08-20	$-0.26	$555,100,610	6 / 6
2026-08-21	$-0.23	$569,314,292	6 / 6
2026-08-22	$-0.23	$569,314,292	6 / 6
2026-08-23	$-0.23	$569,314,292	6 / 6
2026-08-24	$-0.23	$569,314,292	6 / 6
2026-08-25	$-0.23	$569,314,292	6 / 6
2026-08-26	$-0.25	$557,439,292	5 / 6
2026-08-27	$-0.25	$557,439,292	5 / 6
2026-08-28	$-0.25	$557,439,292	6 / 6
2026-08-29	$-0.25	$557,439,292	6 / 6
2026-08-30	$-0.25	$557,439,292	6 / 6
2026-08-31	$-0.25	$557,439,292	6 / 6
2026-09-01	$-0.25	$557,439,292	6 / 6
2026-09-02	$-0.25	$557,439,292	6 / 6
2026-09-03	$-0.25	$557,439,292	6 / 6
2026-09-04	$-0.25	$557,439,292	6 / 6
2026-09-05	$-0.25	$557,439,292	6 / 6
2026-09-06	$-0.25	$557,439,292	6 / 6
2026-09-07	$-0.25	$557,439,292	6 / 6
2026-09-08	$-0.25	$557,439,292	6 / 6
2026-09-09	$-0.25	$557,439,292	6 / 6
2026-09-10	$-0.25	$557,439,292	6 / 6
2026-09-11	$-0.25	$557,439,292	6 / 6
2026-09-12	$-0.25	$557,439,292	6 / 6
2026-09-13	$-0.25	$557,439,292	6 / 6
2026-09-14	$-0.25	$557,439,292	6 / 6
2026-09-15	$-0.25	$557,439,292	6 / 6
2026-09-16	$-0.25	$557,439,292	6 / 6
2026-09-17	$-0.25	$557,439,292	6 / 6
2026-09-18	$-0.23	$557,439,292	6 / 6
2026-09-19	$-0.23	$557,439,292	6 / 6
2026-09-20	$-0.23	$557,439,292	6 / 6
2026-09-21	$-0.23	$557,439,292	6 / 6
2026-09-22	$-0.23	$557,439,292	6 / 6
2026-09-23	$-0.23	$557,439,292	6 / 6
2026-09-24	$-0.23	$557,439,292	6 / 6
2026-09-25	$-0.23	$557,439,292	6 / 6
2026-09-26	$-0.23	$561,034,482	6 / 7
2026-09-27	$-0.23	$561,034,482	6 / 7
2026-09-28	$-0.23	$561,034,482	6 / 7
2026-09-29	$-0.23	$561,034,482	6 / 7
2026-09-30	$-0.21	$572,634,482	6 / 7
2026-10-01	$-0.21	$575,242,837	6 / 7
2026-10-02	$-0.21	$575,244,259	6 / 7
2026-10-03	$-0.21	$575,244,259	6 / 7
2026-10-04	$-0.21	$575,244,259	6 / 7
2026-10-05	$-0.21	$575,244,259	6 / 7
2026-10-06	$-0.21	$575,244,259	6 / 7
2026-10-07	$-0.21	$575,244,259	6 / 7
2026-10-08	$-0.21	$575,244,259	6 / 7
2026-10-09	$-0.19	$587,786,704	6 / 7
2026-10-10	$-0.19	$587,786,704	6 / 7
2026-10-11	$-0.19	$587,786,704	6 / 7
2026-10-12	$-0.19	$587,786,704	6 / 7
2026-10-13	$-0.19	$587,786,704	6 / 7
2026-10-14	$-0.17	$593,631,148	6 / 7
2026-10-15	$-0.17	$593,631,148	6 / 7
2026-10-16	$-0.17	$593,631,148	6 / 7
2026-10-17	$-0.17	$593,631,148	6 / 7
2026-10-18	$-0.17	$593,629,722	6 / 7
2026-10-19	$-0.17	$593,629,722	6 / 7
2026-10-20	$-0.17	$593,629,722	6 / 7
2026-10-21	$-0.17	$593,629,722	6 / 7
2026-10-22	$-0.17	$593,629,722	6 / 7
2026-10-23	$-0.17	$593,629,722	6 / 7
2026-10-24	$-0.17	$593,629,722	6 / 7
2026-10-25	$-0.17	$593,629,722	6 / 7
2026-10-26	$-0.17	$593,629,722	6 / 7
2026-10-27	$-0.17	$593,629,722	6 / 7
2026-10-28	$-0.17	$593,629,722	6 / 7
2026-10-29	$-0.17	$593,629,722	6 / 7
2026-10-30	$-0.17	$593,629,722	6 / 7
2026-10-31	$-0.17	$593,631,148	6 / 7
2026-11-01	$-0.17	$593,631,148	6 / 7
2026-11-02	$-0.17	$593,631,148	6 / 7
2026-11-03	$-0.17	$593,631,148	6 / 7
2026-11-04	$-0.17	$595,540,330	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings